1 |
Henry D, Stehlik P, Camacho X, Pearson SA. Access to routinely collected data for population health research: experiences in Canada and Australia. Aust N Z J Public Health 2018;42(5):430-3.
|
2 |
Leonard CE, Brensinger CM, Nam YH, et al. The quality of Medicaid and Medicare data obtained from CMS and its contractors: implications for pharmacoepidemiology. BMC Health Serv Res 2017;17(1):304.
DOI
|
3 |
Health Insurance Review and Assessment Service. Statistics on national health insurance expenditure 2018. Available from http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020045010000&brdScnBltNo=4&brdBltNo=2315&pageIndex=1#none. Accessed October 15, 2019.
|
4 |
Korea Ministry of Food and Drug. Statistics on food and drug 2018. Available from https://www.mfds.go.kr/brd/m_371/down.do?brd_id=stat0016&seq=30714&data_tp=A&file_seq=1. Accessed October 15, 2019.
|
5 |
Bae EY. Drug reimbursement decisions in Korea, Australia, and Canada. The Korean Journal of Health Economics and Policy 2011;17(4):1-21.
|
6 |
Jung SY, Kim SJ, Kim DS. The review of orphan or anticancer drugs funding programs from foreign countries’ experiences. Yakhak Hoeji 2017;61(2):100-8.
DOI
|
7 |
Lee YS, Bae SJ, Lee BR, et al. Review of risk sharing arrangements in some developed countries: focusing on type of contracts and management system. Journal of Health Technology Assessment. 2017;5(1):13-21.
|
8 |
Lee HJ. The composition of pharmaceutical expenditure in national health insurance and implications for reasonable spending. Health Policy and Management. 2018;28(4):360-8.
DOI
|
9 |
Department of Health. PBS expenditure and prescriptions. Available from http://www.pbs.gov.au/info/statistics/expenditure-prescriptions/pbs-expenditure-and-prescriptions. Accessed October 15, 2019.
|
10 |
Roughead EE, Kim DS, Ong B, Kemp-Casey A. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price. WHO South East Asia J Public Health 2018;7(2):99-106.
DOI
|
11 |
Department of Health. Australian statistics on medicines. Available from https://www.pbs.gov.au/info/statistics/asm/australian-statisticson-medicines. Accessed October 15, 2019.
|
12 |
Department of Health. Information on the australian statistics on medicines. Available from http://www.pbs.gov.au/info/statistics/asm/asm-2015. Accessed October 15, 2019.
|
13 |
Department of Human Services. Pharmaceutical benefits schedule item reports. Available from http://medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp. Accessed October 15, 2019.
|
14 |
Australian Government. National Health Amendment (Pharmaceutical Benefits Scheme) act 2010. Available from https://www.legislation.gov.au/Details/C2010A00126. Accessed October 15, 2019.
|
15 |
Department of Health. Pharmaceutical benefits scheme collection of under co-payment data. Available from http://www.pbs.gov.au/info/statistics/under-co-payment/under-co-payment-data. Accessed October 15, 2019.
|
16 |
Department of Health. Report on the collection of under co-payment data 2017-18. Available from http://www.pbs.gov.au/info/statistics/under-co-payment/ucp-data-report. Accessed October 15, 2019.
|
17 |
Seaman KL, Sanfilippo FM, Roughead EE, et al. Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia. BMJ open 2017;7(6):e013691.
DOI
|
18 |
WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2019. Available from https://www.whocc.no/filearchive/publications/2019_guidelines_web.pdf. Accessed October 15, 2019.
|
19 |
Department of Health. PBS and RPBS Section 85 date of supply data. Available from http://www.pbs.gov.au/info/statistics/dos-anddop/dos-and-dop. Accessed October 15, 2019.
|
20 |
Mellish L, Karanges EA, Litchfield MJ, et al. The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers. BMC Res Notes 2015;8(1):634.
|
21 |
Health Insurance Review and Assessment Service. Statistics on medicines. In: Healthcare Bigdata Hub. Available from http://opendata.hira.or.kr/op/opc/olapMsupInfo.do. Accessed October 15, 2019.
|
22 |
Wettermark B, Zoega H, Furu K, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research-a literature review. Pharmacoepidemiol Drug Saf 2013;22(7):691-9.
DOI
|
23 |
Department of Health. What is the PBS? Available from http://www.pbs. gov.au/info/about-the-pbs#What_is_the_PBS. Accessed October 15, 2019.
|
24 |
Avorn J. In defense of pharmacoepidemiology-embracing the yin and yang of drug research. N Engl J Med 2007;357(22):2219-21.
|
25 |
Chen YC, Wu JC, Haschler I, Majeed A, Chen TJ, Wetter T. Academic impact of a public electronic health database: bibliometric analysis of studies using the general practice research database. PloS One 2011;6(6):e21404.
DOI
|
26 |
Pearson SA, Pesa N, Langton JM, Drew A, Faedo M, Robertson J. Studies using Australia's Pharmaceutical Benefits Scheme data for pharmacoepidemiological research: a systematic review of the published literature (1987-2013). Pharmacoepidemiol Drug Saf 2015;24(5):447-55.
DOI
|